SIM
VIRX

Seaview Investment Managers’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Seaview Investment Managers’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-349
Closed -$2K – 168
2020
Q4 		$2K Buy
349
+1
+0.3% +$5 ﹤0.01% 142
2020
Q3 		$1K Buy
+348
New +$3.04K ﹤0.01% 115

Other funds holding VIRX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Seaview Investment Managers's VIRX Position: Q1 2021 in Review

Seaview Investment Managers sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q1 2021, closing a stake of 349 shares — an estimated $2K sold.

Seaview Investment Managers first reported a position in VIRX in Q3 2020 and held it in 2 quarters. The position peaked at $2K in Q4 2020. 50 funds tracked by Wall St. Rank hold VIRX as of Q1 2021.

  • Seaview Investment Managers reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Seaview Investment Managers sold 349 Viracta Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $2K.
  • Seaview Investment Managers first reported a position in Viracta Therapeutics, Inc. Common Stock in Q3 2020 and held it in 2 quarters.
  • Seaview Investment Managers's Viracta Therapeutics, Inc. Common Stock position peaked at $2K in Q4 2020.
  • 50 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Seaview Investment Managers's 13F filing for Q1 2021, filed 7 May 2021.